Treating cancer is a major health priority in western society. Coupled with attempts to alter unhealthy behaviour, it is hoped that better cancer treatment can reduce premature deaths.
Anti-APE1 mouse monoclonal antibodies from Novus Biologicals were antibodies used to investigate drug resistance in non-small cell lung carcinoma (Wang et al., Lung Cancer 2009, 65(3), pp. 298-304). Tumour drug resistance results in less successful chemotherapy.
Apurinic/apyrimidinic endonuclease (APE1) has a key role in the repair of DNA damage. By protecting cells from the genotoxic and cytotoxic effects of oxidising agents, APE1 counters the development of a number of pathologies.
Conversely, in the case of tumour cells, the protective effects of APE1 will have negative consequences if they result in the tumour having an increased capacity to resist anti-cancer treatment.
-Western%20Blot-NB100-116-img0008.jpg "Western Blot: APE1 Antibody")
Western Blot: APE1 Antibody
Wang and colleagues used anti-APE1 antibodies in immunohistochemical and Western blot studies to investigate APE1 protein expression in tumour samples from patients with non-small cell lung carcinoma. The tumours varied in their resistance to cisplatin chemotherapy. High levels of APE1 expression were seen in 83.3% of resistant tumours, but in only 8.3% of sensitive tumours. Low expression levels of APE1 correlated with longer overall survival and disease-free survival of the patients.
Further studies in a human lung adenocarcinoma cell line showed that cisplatin increased APE1 expression in these cells. Treatment of the cells with an adenoviral vector carrying APE1 siRNA (small interfering RNA) inhibited APE1 expression and increased cell sensitivity to cisplatin.
Novus Biologicals offers many APE1 reagents for your research needs including:
